MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$55,296K
Free Cash flow
$300,925K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Prepaid expenses and other asset...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Payments for repurchases of comm...
Development
Selling, general, and administra...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-07-03
2026-04-03
2026-01-02
2025-10-03
Revenues
628,690
610,812
598,663
597,755
Cost of goods sold
20,657
19,953
26,481
18,574
Drug discovery
18,252
19,476
26,483
23,838
Development
150,522
135,715
146,822
133,645
Selling, general, and administrative
127,413
122,870
109,701
103,129
Other segment items
63,378
61,238
53,914
82,078
Interest income
14,210
16,127
17,426
15,922
Provision for income taxes
50,628
57,220
8,160
58,835
Net income
212,050
210,467
244,528
193,578
Depreciation and amortization
6,984
6,948
6,946
7,422
Impairment of long-lived assets
-
-
0
0
Stock-based compensation
32,563
29,050
20,097
30,885
Non-cash lease expense
5,927
5,994
6,019
6,044
Deferred taxes
-
-
-126,237
-
Acquired in-process research and development technology
8,575
2,025
5,000
6,249
Other, net
1,276
2,019
2,348
-1,356
Trade receivables, net
-6,734
42,031
-22,809
17,370
Inventory
44
3,389
-13,806
4,149
Prepaid expenses and other assets
-40,503
-58,653
97,034
-47,649
Accrued collaboration liabilities
-9,306
4,044
355
903
Accounts payable and other liabilities
5,031
-17,897
-12,900
17,755
Net cash provided by operating activities
307,741
251,845
333,515
290,322
Purchases of marketable securities
68,522
274,161
154,941
189,370
Proceeds from maturities and sales of marketable securities
169,268
225,125
189,339
221,506
Purchases of property, equipment and other, net
6,816
1,509
1,157
1,482
Acquired in-process research and development technology
2,500
525
6,000
5,249
Net cash provided by investing activities
91,430
-51,070
27,241
25,405
Payments for repurchases of common stock
322,974
430,352
257,618
104,035
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan
15,440
7,472
7,875
3,552
Taxes paid related to net share settlement of equity awards
36,341
34,231
4,825
3,377
Net cash used in financing activities
-343,875
-457,111
-254,568
-103,860
Net decrease in cash and cash equivalents
55,296
-256,336
106,188
211,867
Cash and cash equivalents at beginning of period
226,152
482,488
376,300
217,374
Cash and cash equivalents at end of period
281,448
226,152
482,488
376,300
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Revenues
$628,690K
(10.63%↑ Y/Y)
Interest income
$14,210K
(-15.36%↓ Y/Y)
Net income
$212,050K
(14.72%↑ Y/Y)
Prepaid expenses and
other assets
-$40,503K
(-138.68%↓ Y/Y)
Stock-based compensation
$32,563K
(-9.73%↓ Y/Y)
Acquired in-process
research and development...
$8,575K
(1043.33%↑ Y/Y)
Depreciation and
amortization
$6,984K
(-4.88%↓ Y/Y)
Trade receivables,
net
-$6,734K
(-162.83%↓ Y/Y)
Non-cash lease expense
$5,927K
(-2.36%↓ Y/Y)
Proceeds from maturities
and sales of...
$169,268K
(-52.06%↓ Y/Y)
Canceled cashflow
$430,850K
Accounts payable and
other liabilities
$5,031K
(107.92%↑ Y/Y)
Net cash provided by
operating activities
$307,741K
(528.13%↑ Y/Y)
Net cash provided by
investing activities
$91,430K
(-63.14%↓ Y/Y)
Canceled cashflow
$10,626K
Canceled cashflow
$77,838K
Development
$150,522K
(12.20%↑ Y/Y)
Selling, general, and
administrative
$127,413K
(12.82%↑ Y/Y)
Other segment items
$63,378K
(-5.01%↓ Y/Y)
Provision for income taxes
$50,628K
(11.11%↑ Y/Y)
Cost of goods sold
$20,657K
(6.10%↑ Y/Y)
Drug discovery
$18,252K
(-14.54%↓ Y/Y)
Net decrease in cash
and cash...
$55,296K
(386.23%↑ Y/Y)
Canceled cashflow
$343,875K
Accrued collaboration
liabilities
-$9,306K
(-134.76%↓ Y/Y)
Other, net
$1,276K
(-78.12%↓ Y/Y)
Inventory
$44K
(101.67%↑ Y/Y)
Proceeds from issuance of
common stock under the...
$15,440K
(-40.80%↓ Y/Y)
Purchases of marketable
securities
$68,522K
(-32.48%↓ Y/Y)
Purchases of property,
equipment and other, net
$6,816K
(140.17%↑ Y/Y)
Acquired in-process
research and development...
$2,500K
(233.33%↑ Y/Y)
Net cash used in
financing activities
-$343,875K
(-8.70%↓ Y/Y)
Canceled cashflow
$15,440K
Payments for repurchases
of common stock
$322,974K
(6.97%↑ Y/Y)
Taxes paid related to
net share...
$36,341K
(-10.27%↓ Y/Y)
Buy us a coffee
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)